Stockreport

Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Survival results for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan in TROPION-Breast01 did not achieve statistical significance versus chemotherapyTrial previo [Read more]